Rational Design and Synthesis of Highly Stable Haloflavanone DNA Methyltransferase Inhibitors Inducing Tumor...

Area of Science:

• Epigenetics
• Medicinal Chemistry
• Cancer Biology

Background:

• DNA methylation is a key epigenetic regulator implicated in cancer development.
• Current DNA methyltransferase (DNMT) inhibitors like 5-azacytidine have limitations including poor selectivity, stability, and high toxicity.
• Previous work identified 3-halo-3-nitroflavanones as non-nucleoside DNMT inhibitors.

Purpose of the Study:

• To design and synthesize novel 2-substituted haloflavanones with enhanced chemical stability and potency.
• To evaluate the anticancer potential of these new compounds, particularly their DNMT inhibitory activity and effects on cancer cells.
• To investigate the mechanism of action and therapeutic promise of the most effective compound.

Main Methods:

• Chemical synthesis of a new series of 2-substituted haloflavanones.
• In vitro assays to determine DNMT3A inhibitory activity.
• Cell-based assays to assess effects on gene expression, cell proliferation, and cell cycle progression.
• Saturation transfer difference-nuclear magnetic resonance (STD-NMR) and computational docking studies to elucidate the binding mechanism.

Main Results:

• Compound 34b (anti-3-bromo-3-chloro-2-methoxyflavanone) demonstrated submicromolar DNMT3A inhibitory activity.
• 34b upregulated DNMT-targeted genes and significantly impaired cancer cell proliferation.
• The compound induced G1/S cell cycle arrest, even in p53-depleted colorectal cancer cells.
• STD-NMR and computational studies confirmed 34b binds to the DNMT catalytic pocket via distinct poses.

Conclusions:

• The novel haloflavanone 34b exhibits high stability and potent DNMT3A inhibitory activity.
• 34b demonstrates significant anticancer effects, including cell cycle arrest, making it a promising candidate for further therapeutic development.
• This compound represents a potential new class of DNMT inhibitors for anticancer research and therapy.